

**PHONG PHU PHARMACEUTICAL JOINT
STOCK COMPANY**

No.: 09/2026/PP-TCK

*(Re: Explanation of the Difference in net profit after
tax in the Q2/2026 Financial Statements)*

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Ho Chi Minh City, Jul. 22nd, 2026

To: - **STATE SECURITIES COMMISSION OF VIETNAM**
 - **HANOI STOCK EXCHANGE**

Phong Phu Pharmaceutical Joint Stock Company hereby provides an explanation regarding the difference in profit after corporate income tax reported in the Q2/2026 financial statements for the operating period from April 01st, 2026 to June 30, 2026, as follows:

1. Separated Financial Statements for the period from April 01st, 2026 to June 30, 2026:

- Net profit after tax for Q2/2026	: VND 8,630,638,742
- Net profit after tax for Q2/2025	: VND 4,560,039,320
- Increase	: VND 4,070,599,422
- Increase rate	: 89,27%

2. Consolidated Financial Statements for the period from April 01st, 2026 to June 30, 2026:

- Net profit after tax for Q2/2026	: VND 9,133,704,321
- Net profit after tax for Q2/2025	: VND 4,319,191,369
- Increase	: VND 4,814,512,952
- Increase rate	: 111,47%

The increase in profit in the separated financial statements and consolidated financial statements of this period is due to the following reasons:

+ Net Sales revenue in separated financial statements increased by 13.51% and net sales revenue in consolidated financial statements increased by 35,57% compared to the same period last year.

+ Cost of goods sold decreased this period compared to the same period last year because inventory volume increased by 20.15% compared to the same period last year, while fixed costs increased at a lower percentage rate than the increase in inventory volume.

+ Income from financial activities in the separate financial statements increased by 135.08% and in the consolidated financial statements by 74.49% compared to the same period last year due to increased interest from time deposits and profits from the business operations of subsidiaries.

Due to the above reasons, Net profit after tax in the Q2/2026 separated and consolidated financial statements was higher than in the Q2/2025.

Through this letter, Phong Phu Pharmaceutical Joint Stock Company reports and explains to the authorities.

Sincerely.

Recipients:

- *As addressed;*
- *Office archived.*

PHONG PHU PHARMACEUTICAL
JOINT STOCK COMPANY
GENERAL DIRECTOR



Châu Nhã Ngôn